Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR366234 vs Latanoprost in Glaucoma and Ocular Hypertension
NCT02531152Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SAR366234 in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Sanofi. Started Sep 2015; status: completed.
02
Drugs
SAR366234
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02531152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531152.